These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28729054)

  • 21. Novel peptidyl α-aminoalkylphosphonates as inhibitors of hepatitis C virus NS3/4A protease.
    Skoreński M; Pachota M; Pyrć K; Sieńczyk M; Oleksyszyn J
    Antiviral Res; 2017 Aug; 144():286-298. PubMed ID: 28673801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase.
    Dunsdon RM; Greening JR; Jones PS; Jordan S; Wilson FX
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1577-9. PubMed ID: 10915055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
    Kazmierski WM; Hamatake R; Duan M; Wright LL; Smith GK; Jarvest RL; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Wang A; Li X; Zhang S; Zhang YK; Liu Y; Ding CZ; Zhou Y; Plattner JJ; Baker SJ; Bu W; Liu L
    J Med Chem; 2012 Apr; 55(7):3021-6. PubMed ID: 22471376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid.
    Venkatraman S; Njoroge FG; Wu W; Girijavallabhan V; Prongay AJ; Butkiewicz N; Pichardo J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1628-32. PubMed ID: 16413182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.
    Brown AN; McSharry JJ; Adams JR; Kulawy R; Barnard RJ; Newhard W; Corbin A; Hazuda DJ; Louie A; Drusano GL
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1170-81. PubMed ID: 22155837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease.
    Yeung KS; Meanwell NA; Qiu Z; Hernandez D; Zhang S; McPhee F; Weinheimer S; Clark JM; Janc JW
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2355-9. PubMed ID: 11527730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The therapeutic potential of NS3 protease inhibitors in HCV infection.
    Goudreau N; Llinàs-Brunet M
    Expert Opin Investig Drugs; 2005 Sep; 14(9):1129-44. PubMed ID: 16144497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach.
    Palanisamy N; Lennerstrand J
    Interdiscip Sci; 2018 Mar; 10(1):143-156. PubMed ID: 27311576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.
    Llinàs-Brunet M; Bailey M; Fazal G; Ghiro E; Gorys V; Goulet S; Halmos T; Maurice R; Poirier M; Poupart MA; Rancourt J; Thibeault D; Wernic D; Lamarre D
    Bioorg Med Chem Lett; 2000 Oct; 10(20):2267-70. PubMed ID: 11055335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
    J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hexapeptide functionality of cellulose as NS3 protease inhibitors.
    Ibrahim M; Saleh NA; Elshemey WM; Elsayed AA
    Med Chem; 2012 Sep; 8(5):826-30. PubMed ID: 22741792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships.
    Hu K; Zhu Z; Mathahs MM; Tran H; Bommer J; Testa CA; Schmidt WN
    Drug Des Devel Ther; 2020; 14():757-771. PubMed ID: 32158194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy.
    Das D; Pandya M
    Mini Rev Med Chem; 2018; 18(7):584-596. PubMed ID: 28901852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease.
    Barbotte L; Ahmed-Belkacem A; Chevaliez S; Soulier A; Hézode C; Wajcman H; Bartels DJ; Zhou Y; Ardzinski A; Mani N; Rao BG; George S; Kwong A; Pawlotsky JM
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2681-3. PubMed ID: 20368394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of small molecule inhibitors against the NS3/4A serine protease of Hepatitis C virus genotype 3 via highthroughput virtual screening and in vitro evaluations.
    Sakhor W; Teoh TC; Yusof R; Lim SK; Razif MFM
    Trop Biomed; 2020 Sep; 37(3):609-625. PubMed ID: 33612776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus.
    Ingallinella P; Fattori D; Altamura S; Steinkühler C; Koch U; Cicero D; Bazzo R; Cortese R; Bianchi E; Pessi A
    Biochemistry; 2002 Apr; 41(17):5483-92. PubMed ID: 11969409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
    Sheng XC; Appleby T; Butler T; Cai R; Chen X; Cho A; Clarke MO; Cottell J; Delaney WE; Doerffler E; Link J; Ji M; Pakdaman R; Pyun HJ; Wu Q; Xu J; Kim CU
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2629-34. PubMed ID: 22366653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity.
    Hahm B; Back SH; Lee TG; Wimmer E; Jang SK
    Virology; 1996 Dec; 226(2):318-26. PubMed ID: 8955051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
    Qin Z; Wang M; Yan A
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2931-2938. PubMed ID: 28501513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.